Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-26 02:42 | 2025-09-23 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Director, Officer | SELL | $20.03 | 2,800 | $56,084 | 919,092 |
| 2025-09-26 02:44 | 2025-09-23 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Officer | SELL | $20.03 | 1,500 | $30,045 | 931,688 |
| 2025-09-26 03:59 | 2025-09-23 | ALZN | Alzamend Neuro Inc. | AULT MILTON C III | Director, 10% owner | SELL | $2.34 | 97,006 | $226,926 | 11,254 |
| 2025-09-25 23:31 | 2025-09-24 | UTHR | UNITED THERAPEUTICS Corp | CAUSEY CHRISTOPHER | Director | OPT+S | $440.00 | 1,000 | $440,000 | 4,865 |
| 2025-09-25 23:30 | 2025-09-23 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $426.14 | 8,000 | $3,409,081 | 130 |
| 2025-09-25 02:00 | 2025-09-24 | CNTA | Centessa Pharmaceuticals plc | Bush Tia L | Officer | OPT+S | $24.00 | 35,000 | $840,000 | 121,503 |
| 2025-09-24 16:16 | 2025-09-22 | ARVN | Arvinas Inc. | Morrison Briggs | Director | BUY | $7.57 | 30,000 | $227,010 | 76,021 |
| 2025-09-25 02:41 | 2025-09-22 | OKUR | OnKure Therapeutics, Inc. | Leverone Jason A. | Officer | SELL | $2.62 | 303 | $795 | 12,603 |
| 2025-09-25 02:42 | 2025-09-22 | OKUR | OnKure Therapeutics, Inc. | Saccomano Nicholas A | Director, Officer | SELL | $2.62 | 88 | $231 | 3,506 |
| 2025-09-24 23:30 | 2025-09-22 | ORIC | Oric Pharmaceuticals, Inc. | Chacko Jacob | Director, Officer | SELL | $10.80 | 125,000 | $1,349,938 | 656,419 |
| 2025-09-24 23:30 | 2025-09-22 | VSTM | Verastem, Inc. | Calkins Daniel | Officer | SELL | $9.13 | 82 | $748 | 109,838 |
| 2025-09-25 01:49 | 2025-09-22 | BYSI | BeyondSpring Inc. | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% owner | SELL | $1.76 | 11,772 | $20,753 | 1,847,561 |
| 2025-09-25 03:35 | 2025-09-22 | PTGX | Protagonist Therapeutics, Inc | Waddill William D. | Director | SELL | $64.25 | 4,000 | $257,000 | 5,130 |
| 2025-09-25 00:11 | 2025-09-23 | LGND | LIGAND PHARMACEUTICALS INC | Aryeh Jason | Director | SELL | $170.81 | 10,000 | $1,708,088 | 69,289 |
| 2025-09-24 23:14 | 2025-09-23 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Khattar Jack A. | Director, Officer | OPT+S | $47.23 | 29,513 | $1,393,899 | 1,140,883 |
| 2025-09-24 23:05 | 2025-09-22 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | Officer | OPT+S | $25.00 | 10,000 | $250,000 | 89,878 |
| 2025-09-24 13:35 | 2025-09-22 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $416.35 | 22,500 | $9,367,954 | 0 |
| 2025-09-24 00:14 | 2025-09-19 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Officer | SELL | $19.39 | 7,000 | $135,697 | 933,188 |
| 2025-09-24 00:32 | 2025-09-22 | XOMA | XOMA Royalty Corp | BURNS THOMAS M. | Officer | OPT+S | $35.99 | 4,330 | $155,820 | 30,079 |
| 2025-09-24 04:00 | 2025-09-19 | ROIV | Roivant Sciences Ltd. | Venker Eric | Officer | OPT+S | $14.92 | 1,711,000 | $25,524,698 | 1,504,959 |
| 2025-09-23 23:57 | 2025-09-22 | RNA | Avidity Biosciences, Inc. | Hughes Steven George | Officer | OPT+S | $40.58 | 2,208 | $89,601 | 38,867 |
| 2025-09-23 23:22 | 2025-09-22 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Khattar Jack A. | Director, Officer | OPT+S | $47.02 | 16,587 | $779,921 | 1,122,456 |
| 2025-09-23 23:30 | 2025-09-19 | ALZN | Alzamend Neuro Inc. | AULT MILTON C III | Director, 10% owner | SELL | $2.35 | 77,009 | $180,856 | 8,260 |
| 2025-09-23 23:06 | 2025-09-22 | SAVA | FILANA THERAPEUTICS, INC. | Barry Richard | Director, Officer | BUY | $2.28 | 7,172 | $16,352 | 714,675 |
| 2025-09-24 00:07 | 2025-09-23 | CYTK | CYTOKINETICS INC | Malik Fady Ibraham | Officer | OPT+S | $49.28 | 2,000 | $98,560 | 140,610 |
| 2025-09-22 23:00 | 2025-09-19 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $763.10 | 23,665 | $18,058,643 | 95,606,687 |
| 2025-09-23 02:49 | 2025-09-22 | ABEO | Abeona Therapeutics Inc. | O'Malley Brendan M. | Officer | SELL | $5.43 | 688 | $3,736 | 360,129 |
| 2025-09-23 02:00 | 2025-09-22 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | Officer | OPT+S | $115.96 | 10,000 | $1,159,600 | 0 |
| 2025-09-22 16:35 | 2025-09-18 | CALC | CalciMedica, Inc. | Roberts Eric W | Director, Officer, 10% owner | BUY | $3.07 | 2,500 | $7,675 | 84,150 |
| 2025-09-23 00:25 | 2025-09-19 | AQST | Aquestive Therapeutics Inc. | Barber Daniel | Director, Officer | SELL | $6.00 | 400 | $2,400 | 1,014,773 |
| 2025-09-22 23:39 | 2025-09-19 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $414.19 | 8,000 | $3,313,522 | 130 |
| 2025-09-23 01:32 | 2025-09-18 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $40.26 | 7,022 | $282,732 | 31,338 |
| 2025-09-22 23:07 | 2025-09-18 | SAVA | FILANA THERAPEUTICS, INC. | Barry Richard | Director, Officer | BUY | $2.25 | 237,941 | $534,749 | 707,503 |
| 2025-09-23 00:14 | 2025-09-19 | ANIP | Ani Pharmaceuticals Inc. | Davis Krista | Officer | SELL | $98.04 | 1,000 | $98,040 | 60,186 |
| 2025-09-19 23:00 | 2025-09-18 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $764.65 | 106,626 | $81,531,955 | 95,630,352 |
| 2025-09-19 23:05 | 2025-09-17 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | Director, Officer | SELL | $26.32 | 76,420 | $2,011,199 | 46,144 |
| 2025-09-20 02:12 | 2025-09-17 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Director, Officer | SELL | $19.29 | 6,000 | $115,723 | 921,892 |
| 2025-09-20 01:23 | 2025-09-18 | RARE | Ultragenyx Pharmaceutical Inc. | Huizenga Theodore Alan | Officer | SELL | $29.17 | 64 | $1,867 | 50,242 |
| 2025-09-20 04:17 | 2025-09-19 | APLS | Apellis Pharmaceuticals Inc. | Dunlop A. Sinclair | Director | SELL | $22.95 | 31,092 | $713,561 | 68,908 |
| 2025-09-20 01:03 | 2025-09-17 | BYSI | BeyondSpring Inc. | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% owner | SELL | $1.77 | 11,267 | $19,994 | 1,859,333 |
| 2025-09-19 23:50 | 2025-09-17 | ALZN | Alzamend Neuro Inc. | AULT MILTON C III | Director, 10% owner | SELL | $2.47 | 22,991 | $56,696 | 85,269 |
| 2025-09-20 03:46 | 2025-09-18 | PGEN | PRECIGEN, INC. | KIRK RANDAL J | Director, 10% owner | OPT+S | $3.73 | 5,000,252 | $18,653,440 | 8,520,537 |
| 2025-09-19 23:49 | 2025-09-19 | UTHR | UNITED THERAPEUTICS Corp | Olian Judy D. | Director | SELL | $415.43 | 1,800 | $747,768 | 5,045 |
| 2025-09-19 04:30 | 2025-09-16 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Director | SELL | $8.19 | 25,000 | $204,840 | 117,028 |
| 2025-09-18 23:36 | 2025-09-16 | LFVN | Lifevantage Corp | Lewis Darwin | Director | BUY | $10.85 | 450 | $4,882 | 117,217 |
| 2025-09-18 23:23 | 2025-09-16 | ALXO | Alx Oncology Holdings Inc. | Lettmann Jason | Director, Officer | BUY | $1.08 | 92,233 | $99,353 | 305,121 |
| 2025-09-19 02:28 | 2025-09-18 | ROIV | Roivant Sciences Ltd. | Gline Matthew | Director, Officer | BUY | $15.07 | 3,315 | $49,957 | 17,287,081 |
| 2025-09-19 01:16 | 2025-09-16 | VSTM | Verastem, Inc. | Stuglik Brian M | Director | SELL | $9.99 | 587 | $5,864 | 101,739 |
| 2025-09-19 01:11 | 2025-09-16 | VSTM | Verastem, Inc. | Paterson Dan | Director, Officer | SELL | $9.99 | 390 | $3,896 | 442,117 |
| 2025-09-19 01:14 | 2025-09-16 | VSTM | Verastem, Inc. | Gagnon Robert E. | Director | SELL | $9.99 | 281 | $2,807 | 41,961 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.